Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and Immunologic Effects of Afimetoran (BMS-986256) in Healthy Participants
NCT03634995Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2018
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of afimetoran in systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Number of Serious Adverse Events up to 46 days, Number of deaths up to 46 days and 6 more. Started Aug 2018; status: completed.
02
Drugs
afimetoran
03
Conditions
systemic lupus erythematosus (SLE)cutaneous lupus erythematosus (CLE)
Beyond the preview
Go deeper on NCT03634995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03634995.